229 related articles for article (PubMed ID: 31401120)
1. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
2. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
3. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.
Yan W; Markegard E; Dharmaiah S; Urisman A; Drew M; Esposito D; Scheffzek K; Nissley DV; McCormick F; Simanshu DK
Cell Rep; 2020 Jul; 32(3):107909. PubMed ID: 32697994
[TBL] [Abstract][Full Text] [Related]
4. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
Dunzendorfer-Matt T; Mercado EL; Maly K; McCormick F; Scheffzek K
Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7497-502. PubMed ID: 27313208
[TBL] [Abstract][Full Text] [Related]
5. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
Brems H; Legius E
Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
[TBL] [Abstract][Full Text] [Related]
6. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.
Stowe IB; Mercado EL; Stowe TR; Bell EL; Oses-Prieto JA; Hernández H; Burlingame AL; McCormick F
Genes Dev; 2012 Jul; 26(13):1421-6. PubMed ID: 22751498
[TBL] [Abstract][Full Text] [Related]
7. NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.
Führer S; Ahammer L; Ausserbichler A; Scheffzek K; Dunzendorfer-Matt T; Tollinger M
Biomol NMR Assign; 2017 Oct; 11(2):305-308. PubMed ID: 28831766
[TBL] [Abstract][Full Text] [Related]
8. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
Pasmant E; Gilbert-Dussardier B; Petit A; de Laval B; Luscan A; Gruber A; Lapillonne H; Deswarte C; Goussard P; Laurendeau I; Uzan B; Pflumio F; Brizard F; Vabres P; Naguibvena I; Fasola S; Millot F; Porteu F; Vidaud D; Landman-Parker J; Ballerini P
Oncogene; 2015 Jan; 34(5):631-8. PubMed ID: 24469042
[TBL] [Abstract][Full Text] [Related]
9. Legius Syndrome and its Relationship with Neurofibromatosis Type 1.
Denayer E; Legius E
Acta Derm Venereol; 2020 Mar; 100(7):adv00093. PubMed ID: 32147744
[TBL] [Abstract][Full Text] [Related]
10. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
[TBL] [Abstract][Full Text] [Related]
11. One
Pacot L; Burin des Roziers C; Laurendeau I; Briand-Suleau A; Coustier A; Mayard T; Tlemsani C; Faivre L; Thomas Q; Rodriguez D; Blesson S; Dollfus H; Muller YG; Parfait B; Vidaud M; Gilbert-Dussardier B; Yardin C; Dauriat B; Derancourt C; Vidaud D; Pasmant E
Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31443423
[TBL] [Abstract][Full Text] [Related]
12. Moyamoya syndrome in a child with Legius syndrome: Introducing a cerebral vasculopathy to the SPRED1 phenotype?
Pabst L; Carroll J; Lo W; Truxal KV
Am J Med Genet A; 2021 Jan; 185(1):223-227. PubMed ID: 33078527
[TBL] [Abstract][Full Text] [Related]
13. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.
Witkowski L; Dillon MW; Murphy E; S Lebo M; Mason-Suares H
Mol Genet Genomic Med; 2020 Apr; 8(4):e1180. PubMed ID: 32107864
[TBL] [Abstract][Full Text] [Related]
14. Review and update of SPRED1 mutations causing Legius syndrome.
Brems H; Pasmant E; Van Minkelen R; Wimmer K; Upadhyaya M; Legius E; Messiaen L
Hum Mutat; 2012 Nov; 33(11):1538-46. PubMed ID: 22753041
[TBL] [Abstract][Full Text] [Related]
15. Impaired instrumental learning in Spred1
Borrie SC; Horner AE; Yoshimura A; Legius E; Kopanitsa MV; Brems H
Genes Brain Behav; 2021 Jun; 20(5):e12727. PubMed ID: 33624414
[TBL] [Abstract][Full Text] [Related]
16. SPRED proteins provide a NF-ty link to Ras suppression.
McClatchey AI; Cichowski K
Genes Dev; 2012 Jul; 26(14):1515-9. PubMed ID: 22802525
[TBL] [Abstract][Full Text] [Related]
17. [A novel neurocutaneous syndrome: Legius syndrome. A case report].
Cemeli-Cano M; Peña-Segura JL; Fernando-Martínez R; Izquierdo-Álvarez S; Monge-Galindo L; López-Pisón J
Rev Neurol; 2014 Sep; 59(5):209-12. PubMed ID: 25156025
[TBL] [Abstract][Full Text] [Related]
18. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.
Evans DG; Bowers N; Burkitt-Wright E; Miles E; Garg S; Scott-Kitching V; Penman-Splitt M; Dobbie A; Howard E; Ealing J; Vassalo G; Wallace AJ; Newman W; ; Huson SM
EBioMedicine; 2016 May; 7():212-20. PubMed ID: 27322474
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
Abramowicz A; Gos M
Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
